生物制剂依从性对类风湿关节炎治疗达标的影响(4)
[5]Wang GY，Zhang SL，Wang XR，Frog M，Li C，An Y，Li XF，Wang LZ，Wang CH，Wang YF，Yang R，Yan HM，Wang GC，LU X，Liu X，Zhu P，Chen LN，Jin HT，Liu JT，Goo HF，ChenHY，Xie JL，Wei P，Wang JX，Liu XY，Sun L，Cui LF，ShuR，Liu BL，Yu P，Zhang ZL，Li GT，Li ZB，Yang J，Li JF，JiaB，Zhang FX，Tao JM，Lin JY，Wei MQ，Liu XM，Ke D，HuSX，Ye C，Han SL，Yang XY，Li H，Huang CB，Gao M，Lai B，Cheng YJ，Li XF，Song IJ，Yu XX，Wang AX，Wu LJ，WangYH，He L，Sun WW，Gong L，Wang XY，Wang Y，Zhao Y，Li XX，Wang Y，Zhang Y，So Y，Zhang CF，Mu R，Li ZG.Remission of rheumatoid arthritis and potential determinants：anational multi-center cross-sectional survey.Clin Rheumatol，2015，34(2)：221-230.
, 百拇医药
[6]Jin S，Li M，Fang Y，Li Q，Liu J，Duan X，Liu Y，Wu R，ShiX，Wang Y，Jiang Z，Wang Y，YU C，Wang Q，Tian X，ZhaoY，Zeng X;CREDIT Co-authors.Chinese registry of rheumatoidarthritis(CREDIT)：B.prevalence and risk factors of majorcomorbidities in Chinese patients with rheumatoid arthritis.Arth-ritis Res Ther、2017，19(1)：251.
[7]Kyburz D，Gabay C，Michel BA，Finckh A：physicians of SCQ-M-RA.The long-term impact of early treatment of rheumatoidarthritis on radiographic progression：a population-based cohortstudy.Rheumatology(Oxford)，2011，50(6)：1106-1110.
, 百拇医药
[8]Aletaha D，Alasti F，Smolen JS.Optimisation of a treat-to-targetapproach in rheumatoid arthritis：strategies for the 3-month timepoint.Ann Rheum Dis，2016，75(8)：1479-1485.
[9]Gadallah MA，Boulos DN，Gebrel A，Dewedar S，MoriskyDE.Assessment of rheumatoid arthritis patients’adherence totreatment.Am J Med Sci，2015，349(2)：151-156.
[10]Li L，Cui Y，Yin R，Chen S，Zhao Q，Chen H，Shen B.Medication adherence has an impact on disease activity in rheu-matoid arthritis：a systematic review and meta-analysis.PatientPrefer Adherence，2017，11：1343-1356.
, 百拇医药
[11]Xia Y，Yin R，Fu T，Zhang L，Zhang Q，Goo G，Li L，Go Z.Treatment adherence to disease-modifying antirheumatic drugs inChinese patients with rheumatoid arthritis.Patient Prefer Adher-ence，2016，10：735-742.
[12]莫穎倩，毕瑜斐，戴冽，Pierre Miossec.IL-17在局部及全身的致关节炎作用：从发现到靶向治疗.新医学，2018，49(7)：461-467.
[13]Yoshida K，Tokuda Y，Oshikawa H，Utsunomiya M，KobayashiT，Kimura M，Deshpande GA，Matsui K，Kishimoto M.Anobservational study of tocilizumab and TNF-αlpha inhibitor usein a Japanese community hospital：different remission rates，similar drug survival and safety.Rheumatology(Oxford)，2011，50(11)：2093-2099.
[14]Leon L，Rodriguez-Rodriguez L，Rosales Z，Gomez A，LamasJR，Pato E，Jover JA，Abasoln L.Long-term drug survival ofbiological agents in patients with rheumatoid arthritis in clinicalpractice.Scand J Rheumatol，2016，45(6)：456-460., 百拇医药(陈乐锋 马剑达 李谦华 戴冽)
, 百拇医药
[6]Jin S，Li M，Fang Y，Li Q，Liu J，Duan X，Liu Y，Wu R，ShiX，Wang Y，Jiang Z，Wang Y，YU C，Wang Q，Tian X，ZhaoY，Zeng X;CREDIT Co-authors.Chinese registry of rheumatoidarthritis(CREDIT)：B.prevalence and risk factors of majorcomorbidities in Chinese patients with rheumatoid arthritis.Arth-ritis Res Ther、2017，19(1)：251.
[7]Kyburz D，Gabay C，Michel BA，Finckh A：physicians of SCQ-M-RA.The long-term impact of early treatment of rheumatoidarthritis on radiographic progression：a population-based cohortstudy.Rheumatology(Oxford)，2011，50(6)：1106-1110.
, 百拇医药
[8]Aletaha D，Alasti F，Smolen JS.Optimisation of a treat-to-targetapproach in rheumatoid arthritis：strategies for the 3-month timepoint.Ann Rheum Dis，2016，75(8)：1479-1485.
[9]Gadallah MA，Boulos DN，Gebrel A，Dewedar S，MoriskyDE.Assessment of rheumatoid arthritis patients’adherence totreatment.Am J Med Sci，2015，349(2)：151-156.
[10]Li L，Cui Y，Yin R，Chen S，Zhao Q，Chen H，Shen B.Medication adherence has an impact on disease activity in rheu-matoid arthritis：a systematic review and meta-analysis.PatientPrefer Adherence，2017，11：1343-1356.
, 百拇医药
[11]Xia Y，Yin R，Fu T，Zhang L，Zhang Q，Goo G，Li L，Go Z.Treatment adherence to disease-modifying antirheumatic drugs inChinese patients with rheumatoid arthritis.Patient Prefer Adher-ence，2016，10：735-742.
[12]莫穎倩，毕瑜斐，戴冽，Pierre Miossec.IL-17在局部及全身的致关节炎作用：从发现到靶向治疗.新医学，2018，49(7)：461-467.
[13]Yoshida K，Tokuda Y，Oshikawa H，Utsunomiya M，KobayashiT，Kimura M，Deshpande GA，Matsui K，Kishimoto M.Anobservational study of tocilizumab and TNF-αlpha inhibitor usein a Japanese community hospital：different remission rates，similar drug survival and safety.Rheumatology(Oxford)，2011，50(11)：2093-2099.
[14]Leon L，Rodriguez-Rodriguez L，Rosales Z，Gomez A，LamasJR，Pato E，Jover JA，Abasoln L.Long-term drug survival ofbiological agents in patients with rheumatoid arthritis in clinicalpractice.Scand J Rheumatol，2016，45(6)：456-460., 百拇医药(陈乐锋 马剑达 李谦华 戴冽)